Authorization and benefit determination

Coverage depends on the member’s benefit plan and services must meet medical necessity and any applicable authorization requirements for the procedure, diagnosis, and member’s state of residence.

• Check member benefits and plan-specific authorization rules prior to ordering.
• Services not meeting medical necessity or authorization guidelines may be denied or recouped.

Prior authorization likely for serologic/genetic panels

Genetic testing and combinatorial serologic–genetic diagnostic panels are not included in major AGA/ACG diagnostic algorithms and are not recommended for routine diagnosis; prior authorization may be required when such testing is requested outside guideline-supported indications.

• Treat requests for multianalyte or genetic panels as potentially requiring prior authorization when not aligned with guideline indications.

Check prior authorization for listed lab codes

The policy lists applicable CPT/HCPCS and proprietary laboratory procedure codes for fecal and serologic testing; verify plan-specific prior authorization requirements for the listed codes before ordering.

• Document and verify requirements for codes including 83993, 83630, 82397, 83516, 83520, 86036, 86037 and proprietary code 0164U.
• Confirm authorization with the member’s plan for any test that may be excluded from routine coverage.

Prior authorization not specified in this extract

The evidence reference sections in this excerpt present bibliography and do not state any prior authorization requirements for specific tests or codes.

Prior authorization

Bibliography and reference lists do not include authorization instructions; prior authorization determinations are governed by plan benefit documents and may not be specified in these references.

Provider action (reference)

(See supporting references and code list in policy.)

Provider action (guideline context)

(Placeholder — no explicit provider action language in the referenced chunk.)

No step therapy specified

No step therapy requirements are specified in the policy excerpts; clinical guidelines recommend using noninvasive fecal biomarkers (fecal calprotectin, fecal lactoferrin) and CRP to triage suspected IBD prior to invasive testing.

• The policy does not define any step-therapy sequence for laboratory testing.
• Use guideline-recommended noninvasive biomarkers to inform need for endoscopy or further testing.

Provider action (reference)

(Placeholder — no explicit provider action language in the referenced chunk.)

No step therapy stated in references

Publication-history and bibliographic chunks do not state step therapy or utilization-management sequencing for these laboratory tests.

Provider documentation and coding responsibility

Providers are responsible for submission of accurate documentation of services performed and appropriate coding per industry standards; failure to follow coding/billing guidelines or current reimbursement policies may result in denial or recoupment.

• Ensure clinical records support medical necessity and correlate diagnostic codes with ordered tests.
• Follow AMA CPT, HCPCS, ICD-10 and payer-specific billing instructions when submitting claims.

Document fecal calprotectin values and clinical context

When fecal calprotectin is used to monitor ulcerative colitis in symptomatic remission or to assess suspected relapse, document the fecal calprotectin value and the corresponding symptom assessment because guidelines recommend combining biomarkers with symptoms to inform management.

• Record numeric fCal result and clinical context (symptoms, prior therapy, reason for testing).
• Document any subsequent management decisions (endoscopy vs empiric treatment) linked to biomarker results.

Procedure code documentation

Document the specific laboratory procedure code(s) for ordered tests when submitting claims (examples provided in the policy: 83993 for fecal calprotectin; 83630 for fecal lactoferrin; 86036/86037 for ANCA; proprietary code 0164U for certain proprietary assays).

• Include the exact CPT/HCPCS/proprietary code used by the performing lab on the claim.
• Retain supporting clinical documentation that justifies the test and matches the billed code.

Provider action (reference)

(Placeholder — no explicit provider action language in the referenced chunk.)

Publication history note

Publication history records governance approval on 06/16/2026; these publication-history chunks do not specify additional provider documentation requirements.

Documentation/coding noncompliance may trigger denial

Claims may be denied or recouped if coding/billing guidelines or current reimbursement policies are not followed or if documentation is inaccurate or insufficient to support medical necessity.

• Maintain contemporaneous clinical documentation correlating symptoms, test results, and intended management.
• Ensure accurate code selection and adherence to payer billing rules to reduce risk of denial.

Routine serologic/genetic testing not recommended — risk of denial

Routine use of serologic or genetic markers to establish the diagnosis of Crohn’s disease or ulcerative colitis is not indicated or recommended by major societies; using these tests contrary to guideline-supported indications may risk denial of coverage.

• Serologic and genetic tests are complementary or for select indications (eg, VEO-IBD) but are not part of routine diagnostic algorithms.
• When ordering serologic/genetic tests for diagnosis/prognosis outside guideline-supported scenarios, obtain prior authorization and document rationale.

Conflicts with government policies

If there is a conflict between this policy and applicable government policy (for example, LCDs, NCDs, or state Medicaid rules), the government policy will govern determinations; providers should follow the applicable government policy for the member.

• Check applicable Medicare/Medicaid LCDs/NCDs or state regulations when treating members covered by government programs.
• Nonconforming claims may be denied per those regulations.

Authorization/denial triggers not present in references

The reference sections and bibliographic excerpts do not include explicit authorization or denial triggers for tests; authorization decisions are determined by plan benefit documents and medical necessity rules rather than these evidence references.

No denial triggers stated in these sections

No explicit denial triggers are stated in these document sections; denials are linked to lack of medical necessity, insufficient documentation, coding errors, or conflicts with government policies as described elsewhere in the policy.